젠슨 황의 선택, 루닛이 그리는 ‘소버린 AI’ 시대의 의료 혁명 > K-wave Trends

The core agenda of this meeting, "Sovereign AI," refers to a strategy where each nation controls its own infrastructure and data to build an independent AI ecosystem. This concept, which CEO Jensen Huang is strongly promoting worldwide, holds particular significance in the medical field. Because medical data varies by country due to ethnic characteristics and environmental factors, a model that perfectly understands local nuances is essential rather than a general-purpose AI model. Lunit leverages its experience in operating national-level cancer screening programs at this juncture. Its real-world data, successfully gathered from public medical projects in over 10 countries, is a key asset proving that Lunit is the most powerful partner in the era of Sovereign AI.

Lunit’s "L1," a foundation model specialized for medical science highlighted at the event, is evaluated as having achieved both technical efficiency and practicality. L1 is optimized for clinical reasoning and decision support, adopting an efficient structure that delivers high performance without requiring massive computational resources. This means the company is not just obsessed with performance competition, but is aiming for "field-ready AI" that can be immediately utilized in actual medical settings. Achieving excellent results in rigorous global evaluation standards, such as OpenAI’s Health Bench, proves that this technology has already secured international-level reliability. Now, Lunit’s model is establishing itself as core infrastructure leading the digital transformation of entire hospitals, moving beyond a simple diagnostic aid tool.

Lunit’s growth is not limited to independent technological development but is being accelerated through a powerful consortium ecosystem. Currently collaborating with 23 institutions across industry, academia, research, and hospitals to carry out government projects, Lunit is pursuing an open model to broaden the base of medical AI. In particular, it has recently been exploring the practical application of its foundation model in partnership with major medical institutions such as the National Health Insurance Service Ilsan Hospital and Severance Hospital. This collaborative model maximizes the utility of Lunit’s foundation model, laying the groundwork to innovate the entire workflow of medical staff, from analyzing papers to writing medical reports. This is becoming a practical breakthrough for solving chronic issues in the medical field, such as staffing shortages and excessive workloads.

Lunit’s global strategy has been further solidified through its expansion into the U.S. market. In particular, the acquisition of Volpara served as a catalyst for securing a high penetration rate of approximately 23% in the U.S. breast cancer screening market, which became a decisive move for Lunit to dominate global infrastructure. By providing infrastructure that automates and connects the entire screening journey rather than just selling diagnostic solutions, Lunit is positioning itself as a "problem solver" that addresses the structural challenges of the U.S. healthcare system. This market dominance is another reason why global giants like NVIDIA cannot help but pay attention to Lunit. Lunit is now evolving from a solution provider into an architect of global medical AI infrastructure.

It is highly significant that Lunit, which was selected as one of the world’s top 5 AI startups in NVIDIA’s startup acceleration program "Inception Awards" back in 2017, has now grown into a leader discussing ecosystem building on equal footing with NVIDIA. As Chief Technology Officer (CTO) Sung-won Yoo emphasized at the meeting, every country is craving reliable AI that reflects the data of its own citizens. Lunit is providing a technical solution that precisely addresses this demand. The experience and technology possessed by Lunit will serve as a powerful link to bind fragmented medical data together. The collaboration with NVIDIA is likely to be more than just a business meeting; it is the starting point of a grand journey to establish global medical AI standards.